165 related articles for article (PubMed ID: 37391567)
21. Efficacy of low-dose intravenous cyclophosphamide in systemic lupus erythematosus presenting with Guillain-Barre syndrome-like acute axonal neuropathies: report of two cases.
Santiago-Casas Y; Peredo RA; Vilá LM
Lupus; 2013 Mar; 22(3):324-7. PubMed ID: 23439473
[TBL] [Abstract][Full Text] [Related]
22. Brief Report: The Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen Does Not Impact the Ovarian Reserve, as Measured by Serum Levels of Anti-Müllerian Hormone.
Tamirou F; Husson SN; Gruson D; Debiève F; Lauwerys BR; Houssiau FA
Arthritis Rheumatol; 2017 Jun; 69(6):1267-1271. PubMed ID: 28235250
[TBL] [Abstract][Full Text] [Related]
23. Guillain-Barre Syndrome as Presenting Feature in a Patient with Systemic Lupus Erythematosus.
Beedkar A; Sonawale A; Kawale J
J Assoc Physicians India; 2018 Apr; 66(4):67-8. PubMed ID: 30347958
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.
Mok CC; Lau CS; Wong RW
Arthritis Rheum; 1998 May; 41(5):831-7. PubMed ID: 9588734
[TBL] [Abstract][Full Text] [Related]
25. [Cyclophosphamide induced amenorrhoea in pre-menopausal women with systemic lupus erythematosus].
Cunha I; Saavedra MJ; Pereira da Silva JA; Malcata A
Acta Reumatol Port; 2008; 33(1):69-76. PubMed ID: 18344924
[TBL] [Abstract][Full Text] [Related]
26. Papulonodular mucinosis, Guillain-Barré syndrome and nephrotic syndrome in a patient with systemic lupus erythematosus: a case report.
Su X; Qiao X; Li J; Gao L; Wang C; Wang L
BMC Nephrol; 2017 Feb; 18(1):43. PubMed ID: 28143420
[TBL] [Abstract][Full Text] [Related]
27. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
Mok CC; Ying KY; Tang S; Leung CY; Lee KW; Ng WL; Wong RW; Lau CS
Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470
[TBL] [Abstract][Full Text] [Related]
28. Immunosuppressive therapy of systemic lupus erythematosus associated peripheral neuropathy: A systematic review.
Constantin A; Năstase D; Tulbă D; Bălănescu P; Băicuș C
Lupus; 2020 Oct; 29(12):1509-1519. PubMed ID: 32757735
[TBL] [Abstract][Full Text] [Related]
29. Description of therapeutic strategies in severe systemic lupus erythematosus-associated immune thrombocytopenia: a retrospective cohort study of response and relapse.
Cimé-Aké E; Barrera-Vargas A; Demichelis-Gómez R; Ramírez-Alemón M; Rull-Gabayet M
Clin Rheumatol; 2024 Jun; ():. PubMed ID: 38916764
[TBL] [Abstract][Full Text] [Related]
30. A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: an Egyptian experience.
Sabry A; Abo-Zenah H; Medhat T; Sheashaa H; Mahmoud K; El-Huseini A
Int Urol Nephrol; 2009; 41(1):153-61. PubMed ID: 18214709
[TBL] [Abstract][Full Text] [Related]
31. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus.
Fassbinder T; Saunders U; Mickholz E; Jung E; Becker H; Schlüter B; Jacobi AM
Arthritis Res Ther; 2015 Apr; 17(1):92. PubMed ID: 25890338
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of premature ovarian failure in systemic lupus erythematosus patients treated with immunosuppressive agents in Thailand.
Akawatcharangura P; Taechakraichana N; Osiri M
Lupus; 2016 Apr; 25(4):436-44. PubMed ID: 26621134
[TBL] [Abstract][Full Text] [Related]
33. Guillian-Barre syndrome as the initial presentation of systemic lupus erythematosus--case report and review of literature.
Nadri Q; Althaf MM
Ann Saudi Med; 2015; 35(3):263-5. PubMed ID: 26409804
[TBL] [Abstract][Full Text] [Related]
34. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus.
Pryor BD; Bologna SG; Kahl LE
Arthritis Rheum; 1996 Sep; 39(9):1475-82. PubMed ID: 8814058
[TBL] [Abstract][Full Text] [Related]
35. Guillain-Barré Syndrome Complicated by Posterior Reversible Encephalopathy Syndrome and Reversible Cerebral Vasoconstriction Syndrome.
Kobayashi H; Hoshina Y; Higa H; Watari T
Eur J Case Rep Intern Med; 2023; 10(10):003949. PubMed ID: 37789979
[TBL] [Abstract][Full Text] [Related]
36. Intravenous immunoglobulin for Guillain-Barré syndrome.
Hughes RA; Swan AV; van Doorn PA
Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD002063. PubMed ID: 25238327
[TBL] [Abstract][Full Text] [Related]
37. Changes in immune cell frequencies after cyclophosphamide or mycophenolate mofetil treatments in patients with systemic lupus erythematosus.
Zhao L; Jiang Z; Jiang Y; Ma N; Wang K; Zhang Y
Clin Rheumatol; 2012 Jun; 31(6):951-9. PubMed ID: 22349930
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus.
Cheng H; Zhang XY; Yang HD; Yu Z; Yan CL; Gao C; Wen HY
Front Immunol; 2022; 13():911730. PubMed ID: 35979351
[TBL] [Abstract][Full Text] [Related]
39. Influence of glutathione S transferase A1 gene polymorphism (-69C > T, rs3957356) on intravenous cyclophosphamide efficacy and side effects: a case-control study in Egyptian patients with lupus nephritis.
Attia DHS; Eissa M; Samy LA; Khattab RA
Clin Rheumatol; 2021 Feb; 40(2):753-762. PubMed ID: 32661806
[TBL] [Abstract][Full Text] [Related]
40. Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review.
Aladawi M; Elfil M; Abu-Esheh B; Abu Jazar D; Armouti A; Bayoumi A; Piccione E
Can J Neurol Sci; 2022 Jan; 49(1):38-48. PubMed ID: 33949300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
